Table 1. Baseline patient’s characteristics.
| IV (n = 311) |
AS (n = 153) |
p-valuea | |||
|---|---|---|---|---|---|
| Age (year) | 63.42 (16.43) | 67.03 (14.37) | 0.021 | ||
| Sex | Man | Woman | Man | Woman | 0.302 |
| 198 (63.67) | 113 (36.33) | 105 (68.63) | 48 (31.37) | ||
| Height (cm) | 162.72 (9.92) | 164.45 (8.56) | 0.065 | ||
| ABW (kg) | 60.67 (12.55) | 61.89 (11.62) | 0.313 | ||
| IBW (kg) | 57.53 (10.44) | 59.34 (9.53) | 0.070 | ||
| Duration of colistin use (day) | 13.07 (12.93) | 12.61 (9.80) | 0.702 | ||
| Baseline SCr (mg/dL) | 1.00 (1.03) | 0.85 (0.88) | 0.116 | ||
| Baseline eGFR (mL/min/1.73 m2) | 129.24 (99.90) | 142.40 (92.08) | 0.172 | ||
| Baseline BUN (mg/dL) | 32.62 (23.30) | 29.41 (18.75) | 0.111 | ||
| Underlying diseases (%) | |||||
| Hypertension | 192 (61.74) | 101 (66.01) | 0.416 | ||
| Diabetes mellitus | 107 (34.41) | 57 (37.25) | 0.606 | ||
| Chronic kidney disease | 78 (25.08) | 27 (17.65) | 0.077 | ||
| Type of pathogens (%) | 0.009 | ||||
| Acinetobacter baumannii | 146 (46.95) | 64 (41.83) | |||
| Pseudomonas aeruginosa | 76 (24.44) | 28 (18.30) | |||
| Staphylococcus aureus | 50 (16.08) | 31 (20.26) | |||
| Enterococcus | 18 (5.79) | 6 (3.92) | |||
| Klebsiella pneumoniae | 5 (1.61) | 3 (1.96) | |||
| Other gram-negative pathogens | 14 (4.50) | 18 (11.76) | |||
| Unknown | 2 (0.64) | 3 (1.96) | |||
| ICU patients | 136 (43.73) | 97 (63.40) | < 0.001 | ||
| APACHE2 scoreb | 24.55 (8.56) | 24.49 (8.17) | 0.960 | ||
| Accumulated dose (mg) | 4388.03 (4714.22) | 3112.85 (3065.82) | 0.001 | ||
| Daily dose (mg) | 366.27 (174.77) | 240.71 (93.59) | <0.001 | ||
| Daily dose per ABW (mg/kg/d) | 6.30 (3.62) | 4.02 (1.74) | <0.001 | ||
| Daily dose per IBW (mg/kg/d) | 6.81 (6.29) | 4.19 (1.86) | <0.001 | ||
| Nephrotoxins (%) | |||||
| Amphotericin B (Liposomal) | 31 (9.97) | 7 (4.58) | 0.049 | ||
| Amphotericin B (Deoxycholate) | 46 (14.79) | 15 (9.80) | 0.146 | ||
| NSAIDs | 79 (25.40) | 43 (28.10) | 0.575 | ||
| ACE inhibitors | 6 (1.93) | 1 (0.65) | 0.434 | ||
| ARBs | 21 (6.75) | 11 (7.19) | 0.848 | ||
| Vasopressor | 228 (73.31) | 108 (70.59) | 0.581 | ||
| Diuretics | 57 (18.33) | 53 (34.64) | <0.001 | ||
| Aminoglycosides | 4 (1.29) | 3 (1.96) | 0.689 | ||
| Rifampin | 18 (5.79) | 10 (6.54) | 0.836 | ||
| Vancomycin | 93 (29.90) | 22 (14.38) | <0.001 | ||
| Cyclosporine | 5 (1.61) | 0 (0.00) | 0.176 | ||
| Tacrolimus | 18 (5.79) | 20 (13.07) | 0.011 | ||
| Radiocontrast | 29 (9.32) | 9 (5.88) | 0.279 | ||
Data are presented as mean and SD for continuous data and number of subjects and proportion for categorical data. Categorical data are sex, underlying diseases, site of infection, type of pathogens, ICU patients, and nephrotoxic drugs. ABW, actual body weight; IBW, ideal body weights; SCr, serum creatinine; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; NSAIDs, non-steroidal anti-inflammatory drugs; ACE inhibitors, acetylcholinesterase inhibitors; ARBs, angiotensin receptor blockers
ap-value was calculated by independent t-test for continuous data and Fisher's exact test for categorical data using SPSS ver.23 (IBM corporation, Armonk, New York, U.S.)
bAPACHE2 score was calculated only in ICU patients.